Palvella Therapeutics (PVLA) Change in Account Payables (2014 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Change in Account Payables of $851000.0 for Q1 2026, down 24.29% year-over-year from $1.1 million in Q1 2025, and down 26.38% quarter-over-quarter from $1.2 million in Q4 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Change in Account Payables (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Change in Account Payables for 7 consecutive years, with $851000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 24.29% year-over-year to $851000.0; the TTM figure through Mar 2026 stood at $987000.0 (down 69.88% YoY), while the FY2025 annual figure was $1.3 million, down 43.7% from the prior year.
- Change in Account Payables retreated to $851000.0 in Q1 2026 per PVLA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.7 million in Q3 2024 and bottomed at -$1.1 million in Q3 2025.
- Historically, Change in Account Payables has averaged $483222.2 across 3 years, with a median of $425000.0 in 2024.
- On a YoY basis, Change in Account Payables climbed as much as 2588.37% in 2025 and fell as far as 167.42% in 2025.
- Palvella Therapeutics' Change in Account Payables stood at $43000.0 in 2024, then jumped by 2588.37% to $1.2 million in 2025, then decreased by 26.38% to $851000.0 in 2026.
- Business Quant data shows PVLA's Change in Account Payables at $851000.0 in Q1 2026, $1.2 million in Q4 2025, and -$1.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | 1.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.35 Mn |
| Mar 31, 2026 | 851,000.00 |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | 116,000.00 |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 43,000.00 |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 425,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Dec 31, 2017 | -186,768.00 |
| Sep 30, 2017 | -2.13 Mn |
| Jun 30, 2017 | 1.72 Mn |
| Mar 31, 2017 | 263,025.00 |
| Dec 31, 2016 | -1.94 Mn |
| Sep 30, 2016 | 2.95 Mn |
| Jun 30, 2016 | -246,647.00 |
| Mar 31, 2016 | 597,189.00 |
| Dec 31, 2015 | -41,497.00 |
| Sep 30, 2015 | -946,557.00 |